Welcome to our dedicated page for Turn Therapeutics news (Ticker: TTRX), a resource for investors and traders seeking the latest updates and insights on Turn Therapeutics stock.
Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.
News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.
Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.
Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.
Turn Therapeutics (Nasdaq:TTRX) reported interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis from the first 50 completed subjects. At Week 4, 92.6% of GX-03 patients achieved EASI-50 vs 65.2% on vehicle; EASI-90 was 44.4% vs 30.4%, rising to 51.9% vs 34.8% by Week 8.
No treatment-related serious adverse events, tolerability issues, or discontinuations were observed. Interim findings are being used to refine enrollment criteria, endpoint hierarchy, and focus on earlier inflammatory endpoints as enrollment nears the original target. The company is preparing FDA interactions on regulatory pathways.
Turn Therapeutics (Nasdaq:TTRX) reported a peer-reviewed publication in the Journal of Dermatological Treatment detailing GX-03 activity in an IL-36–associated Staphylococcus aureus-induced murine dermatitis model. GX-03 is the company’s lead program, currently in Phase 2 for moderate-to-severe atopic dermatitis.
Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls (p = 0.0003), with no treatment-related adverse effects observed. The article is the first in a planned series exploring GX-03’s localized, non-systemic mechanism.
Turn Therapeutics (Nasdaq:TTRX), a clinical-stage biotech focused on localized therapies for inflammatory skin diseases, will present at the Jefferies Global Healthcare Conference 2026 in New York City.
CEO Bradley Burnam presents on June 4, 2026, 9:55–10:25 AM EDT, with live and replay webcasts available.
Turn Therapeutics (Nasdaq:TTRX) appointed Stephen M. Hahn, M.D., former FDA Commissioner, as executive clinical and regulatory lead.
He will oversee strategy for GX-03, an investigational topical therapy in a Phase 2 trial for moderate-to-severe atopic dermatitis and other inflammatory skin disease indications.
Turn Therapeutics (Nasdaq:TTRX) reported Q1 2026 results and clinical progress. A Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis is ongoing, with interim data expected Q2 2026 and topline results mid-2026.
The company closed a growth capital facility with Avenue Capital providing access to up to $25 million in term loans, including an initial $7 million tranche. As of March 31, 2026, cash was $11.2 million versus $5.1 million at year-end 2025. Q1 2026 net loss was $971k versus $329k in Q1 2025, as operating expenses rose to $1.25 million. GX-03 is also being advanced toward a potential onychomycosis program.
Turn Therapeutics (Nasdaq: TTRX) reported full-year 2025 results and corporate updates. Key highlights: Phase 2 GX-03 topline expected mid-2026; secured a 42-month venture debt facility up to $25.0M with an initial $7.0M tranche; cash of $5.08M as of Dec 31, 2025 (excludes $7.0M); Medline supply and license agreement could enable revenue in late 2026. Financials: GAAP net loss of $3.19M, G&A of $5.59M, R&D of $0.27M, total assets $12.16M, and 27.72M weighted-average shares outstanding.
Board and leadership strengthened with appointments of Dr. Robert Redfield and Martin Dewhurst to support development, regulatory and strategic initiatives.
Turn Therapeutics (Nasdaq: TTRX) entered a growth capital loan facility with Avenue Venture Opportunities Fund II for up to $25 million, including an initial $7 million tranche funded at closing and up to $18 million tied to clinical and corporate milestones.
Funds are expected to extend runway through the Phase 2 atopic dermatitis readout and, if fully drawn, through the end of 2027 while supporting registrational preparations for GX-03.
Turn Therapeutics (Nasdaq: TTRX) appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs on February 17, 2026.
Dr. Redfield, former CDC director, will advise on clinical development, public health implications, and regulatory strategy for the company’s lead investigational therapy GX-03, currently in Phase 2 trials.
Turn Therapeutics (Nasdaq: TTRX) announced CEO Brad Burnam will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (virtual) on Feb 25, 2026, 8:00–8:30 a.m. ET and at the 46th Annual TD Cowen Healthcare Conference in Boston on Mar 2, 2026, 1:10–1:40 p.m. ET.
Management will update the dermatology pipeline, including the ongoing Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, and will hold one-on-one investor meetings. Webcasts and replays will be available on the company’s Investors website for approximately 30 days.
Turn Therapeutics (Nasdaq: TTRX) provided corporate, pipeline, and financial updates ahead of the 2026 J.P. Morgan Healthcare Conference. Key items include a Phase 2 randomized trial of GX-03 for moderate‑severe atopic dermatitis on track with both interim and topline data expected in H1 2026, the appointment of Martin Dewhurst to the board, and an expanded intranasal vaccine program adding an influenza candidate with in‑vitro and in‑vivo studies planned in Q1 2026. A strategic partnership with Medline is expected to generate near‑term revenue in 2026. The company used a share purchase agreement to bolster cash, extending operational runway into late 2026.